Study summary
Matching targeted drugs to tumor genes, plus immunotherapy, extended survival
19months median survival, against about 5 months historically
What was tested
Each person got a targeted drug matched to their tumor's gene change (BRAF, RAS, or neither), plus the immunotherapy atezolizumab. No comparison group; compared with past results.
What they found
- Median survival across all groups was 19 months, compared with a historical 5 months.
- People with the BRAF change lived longest, a median of 43 months.
- This was a single-center study without a randomized comparison.
What it means
Supports testing every tumor for gene changes and combining targeted drugs with immunotherapy.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.